Attovia Therapeutics to Present New Data on ATTO-1310 and ATTO-2306 at EADV and FCD Conferences

SAN CARLOS, Calif., Sept. 28, 2026 /CourierPR/ -- Attovia Therapeutics, a clinical-stage biopharmaceutical company developing next-generation biotherapeutics for immune-mediated diseases, will present new clinical, translational, and preclinical data across its pipeline at the European Academy of Dermatology and Venereology (EADV) Congress 2026 and the Fall Clinical Dermatology Conference (FCD) 2026. The presentations will take place from September 30 to October 3, 2026, in Vienna, Austria, and from October 8 to 11, 2026, in Las Vegas, Nevada, respectively.

At the EADV Congress 2026, Attovia will present four posters. Three of these will focus on ATTO-1310, a next-generation anti-IL-31 ATTOBODY-based therapeutic. The posters will highlight Phase 1a data in healthy volunteers, translational data advancing the understanding of IL-31 across pruritic skin diseases, and interim Phase 1b data in patients with high-itch atopic dermatitis (AD) or chronic pruritus. The fourth poster will feature new preclinical data on ATTO-2306, a novel long-acting anti-IL-31 and IL-13 bispecific.

Following each congress, the posters will be available on the Publications page of the Attovia website at www.attovia.com.

Attovia's lead programs include ATTO-1310, an anti-IL-31 ATTOBODY-based therapeutic in clinical development for chronic pruritic diseases; ATTO-2306, a long-acting bispecific antibody targeting IL-31 and IL-13 in IND-enabling studies for atopic dermatitis and other immune-mediated skin diseases; and ATTO-1091, a trispecific antibody targeting TL1A, IL-23p19, and integrin α4β7 in IND-enabling studies for inflammatory bowel disease. The company's other programs include highly innovative conditional ‘AND’ gated bispecific immune cell survival blockers and multispecifics.

The company's ATTOBODY platform uses an evolution-driven, high-throughput process that allows for rapid discovery and creation of a high diversity of potential product candidates. All of its product candidates have been internally discovered using this platform. Attovia's ATTOBODY platform is designed to create next-generation biotherapeutics for immune-mediated diseases with high unmet need.

The presentations at the EADV Congress 2026 and the FCD 2026 will provide valuable insights into the ongoing development of ATTO-1310 and ATTO-2306, potentially advancing the treatment of chronic pruritic diseases and other immune-mediated skin conditions. These presentations will be of significant interest to dermatologists, researchers, and healthcare professionals working in the field of dermatology and immunology.